Kinda seems like they are feeling confident about their future.
BioMed Realty Announces Illumina, Inc., As Sole Tenant For San Diego i3 Campus
Genomics Leader Will Lease the Entire 316,000 Square Foot Campus for Office Expansion
"The i3 lease agreement marks the third major lease for new construction that BioMed Realty and Illumina have completed within the last 15 months."
From today's press release, and I couldn't agree more--
In order to efficiently advance product candidates through the clinical trial process, we have historically created operating subsidiaries for each program and product line. This approach has fostered efficient use of resources and reduced shareholder dilution as compared to strategies commonly deployed by the biotechnology industry...
JNJ will have to pay for this technology (Geron receives royalties) plus Asterias' stem cell technology (Geron receives royalties).
Buying Geron will NOT be cheap--especially if we hear news soon from OPC1 trial for spinal injury.
If patients in Asterias' dose-escalation trial have improvements in sensation (as some did in the first, low-dose cohort. Look out. VERY low float.
I couldn't agree more. First, additional warrants from BioTime after their spin-off and now additional warrants for Asterias shares--all at no cost.
I know, I know--could be worthless, but I don't think so. Liking what I'm hearing especially from Asterias--and remember, when Asterias does well, so does Geron AND BioTime. Good luck to all longs of good will.